Abstract Library

#4503 Duodenopancreatic neuroendocrine tumour in MEN1: Gender difference and survival rates

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common inherited syndrome associated with NET development and metastatic duodenal-pancreatic (DP) NET is the main cause of death.

Conference:

Presenting Author: Liccardi A

Authors: Liccardi A, Roberto M, Cannavale G, Benevento E, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1, neuroendocrine tumour, gender difference, survival,

#3971 Clinical manifestation and aggressiveness of duodenopancreatic neuroendocrine tumors (DP-NET) in patients with MEN1 syndrome: A possible role of exon 2 mutations in menin gene

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome characterized by co-occurrence of primary hyperparathyroidism (PH), duodenopancreatic neuroendocrine tumors (DP-NET) and/or pituitary adenomas without an established genotype-phenotype correlation.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1 (MEN1), exon two, genomic, primary hyperparathyroidism, duodenopancreatic neuroendocrine tumor, DP-NET, pituitary adenomas,

#3303 Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study

Introduction: Following European guidelines, patients (pts) with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumors (NETs), should receive systemic combination of chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lepage C

Authors: Lepage C, Phelip J, Lievre A, Le Malicot K, Dahan L,

Keywords: clinical trial, non-resectable, duodeno-pancreatic, neuroendocrine tumor, maintenance,

#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modica R

Authors: Modica R, Lo Calzo F, De Cicco F, Bottiglieri F, Sciammarella C,

Keywords: neuroendocrine tumor, MEN1 syndrome, duodeno pancreatic tumor.,